• CDC News
  • Adult Immunization
  • Hepatology
  • Rare Disorders
  • Pediatric Immunization
  • Weight Management
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Kidney Disease
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Orthopedics
  • Obesity Medicine
  • Rheumatology
  • Technology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

ACE Inhibitors Not Always an Ace Treatment in Patients With Diabetes

News
Article

I recently diagnosed type 2 diabetes mellitus in a 33-year-old man who has no diabeticsymptoms, proteinuria, or evidence of nephropathy. His blood pressure is low(100/60 mm Hg).

I recently diagnosed type 2 diabetes mellitus in a 33-year-old man who has no diabeticsymptoms, proteinuria, or evidence of nephropathy. His blood pressure is low(100/60 mm Hg). Is an angiotensin-converting enzyme (ACE) inhibitor appropriatein this setting?---- Kiron Malhotra, MD
Melbourne, FlaBlood pressure control is the recommended treatment for preventionof diabetic nephropathy, and it is now considered standard-of-care toinclude ACE inhibitors or angiotensin receptor blockers in the antihypertensiveregimen. Your patient is mildly hypotensive; thus, an ACEinhibitor might well provoke a fall in blood pressure that could producesignificant symptoms. In addition, his low blood pressure might be symptomaticof underlying autonomic neuropathy, and an ACE inhibitor would certainlybe contraindicated in that setting.---- Rachmel Cherner, MD
Associate Clinical Professor of Medicine
Jefferson Medical College of Thomas Jefferson University
Philadelphia

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Related Content
Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial / image credit ©Starmarpro/stock.adobe.com

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

Grace Halsey
January 17th 2025
Article

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

Patient Care Staff
January 17th 2025
Article

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces / image credit courtesy of Mayo Clinic

CAH Update: High-Level Examination of Condition Published in Expert Review of Endocrinology & Metabolism, Neurocrine Announces

Grace Halsey
January 16th 2025
Article

"Glucocorticoid therapy in classic congenital adrenal hyperplasia: traditional and new treatment paradigms," offers an in-depth look at the disorder and promising therapies.

GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management / image credit ©brovarky/stock.adobe.com

GLP-1/GIP Dual Agonist HRS9531 Shows Promising Phase 2 Data for Obesity Management

Grace Halsey
January 15th 2025
Article

More than half of study participants receiving the dual incretin agonist had weight loss of 20% or greater, with no evidence of a plateau and only mild AEs.

© 2025 MJH Life Sciences

All rights reserved.